ITGR logo

Integer Holdings Corporation Stock Price

NYSE:ITGR Community·US$3.0b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

ITGR Share Price Performance

US$89.28
89.28 (0.00%)
US$95.00
Fair Value
US$89.28
89.28 (0.00%)
6.0% undervalued intrinsic discount
US$95.00
Fair Value
Price US$89.28
AnalystConsensusTarget US$95.00

ITGR Community Narratives

·
Fair Value US$95 6.0% undervalued intrinsic discount

ITGR: Shares Will Recover As Demand Normalizes And Inventory Pressures Ease

0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
US$95
6.0% undervalued intrinsic discount
Revenue
3.76% p.a.
Profit Margin
8.14%
Future PE
22.3x
Price in 2029
US$120.22

Trending Discussion

Updated Narratives

ITGR logo

ITGR: Fair View Sees 2026 Product Drag Easing As Portfolio Review Progresses

Fair Value: US$95 6.0% undervalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Undervalued with solid track record.

1 Risk
4 Rewards

Integer Holdings Corporation Key Details

US$1.9b

Revenue

US$1.4b

Cost of Revenue

US$497.6m

Gross Profit

US$355.8m

Other Expenses

US$141.8m

Earnings

Last Reported Earnings
Apr 03, 2026
Next Reporting Earnings
n/a
4.18
26.81%
7.64%
73.8%
View Full Analysis

About ITGR

Founded
1970
Employees
11000
CEO
Payman Khales
WebsiteView website
www.integer.net

Integer Holdings Corporation operates as a medical device contract development and manufacturing company in the United States, Costa Rica, Puerto Rico, Ireland, and internationally. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures. It also provides cardiac rhythm management products, including implantable pacemakers, implantable cardioverter defibrillators, insertable cardiac monitors, implantable cardiac pacing and defibrillation leads, and heart failure therapies; implanted medical devices, implanted leads, procedure accessories, and external devices; neuromodulation products, such as implantable spinal cord stimulators; and non-rechargeable batteries, feedthroughs, device enclosures, machined components, and lead components and sub-assemblies. In addition, the company offers rechargeable batteries and chargers; orthopedics, minimally invasive surgery, and general surgery devices; and portable medical devices, including patient monitoring, ventilators, portable defibrillators, portable ultrasound, and X-Ray machines. Furthermore, the company provides medical technologies; supplies medical stamped components, and shallow and deep draw casings and assemblies; and epicardial pacing leads. It serves multi-national original equipment manufacturers and affiliated subsidiaries in the cardiac rhythm management, neuromodulation, orthopedics, cardio and vascular, and advanced surgical and portable medical markets. The company provides its products under the Greatbatch Medical and the Lake Region Medical brands. The company was formerly known as Greatbatch, Inc. and changed its name to Integer Holdings Corporation in July 2016. Integer Holdings Corporation was founded in 1970 and is headquartered in Plano, Texas.

Recent ITGR News & Updates

Seeking Alpha May 21

Integer Holdings: Rare Public Asset Soon To Be Sold

Summary Integer Holdings Corp. is a unique, high-quality medical device CDMO trading at a depressed ~10x EBITDA multiple after a temporary growth slowdown. A strategic review, prompted by activist involvement and heightened buyer interest, positions ITGR for a likely sale within three to four months. Precedent CDMO transactions support a fair value of $110–125/share (13–14x forward EBITDA), offering 20–40% upside with limited downside risk. ITGR’s entrenched OEM relationships, high switching costs, and diversified pipeline underpin its competitive moat and long-term growth prospects. Read the full article on Seeking Alpha
Narrative Update May 07

ITGR: Fair View Sees 2026 Product Drag Easing As Portfolio Review Progresses

Integer Holdings' analyst fair value estimate has increased from $93.25 to $95.00 as analysts factor in updated price targets from Citi, BofA, and Raymond James, along with more cautious assumptions for growth, margins, and future P/E multiples. Analyst Commentary Bullish Takeaways Bullish analysts see room for upside in the stock as recent price targets such as US$101 indicate confidence in the company’s ability to support a higher valuation over time.

Recent updates

No updates